Cargando…

Systemic Sequential Therapy of CisGem, Tislelizumab, and Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma Conversion Therapy

Intrahepatic cholangiocarcinoma (CCA), always diagnosed at an advanced stage in recent years, is of high aggression and poor prognosis. There is no standard treatment beyond first-line chemotherapy and no molecular-targeted agents or immune checkpoint inhibitors approved for advanced intrahepatic CC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Yuan, Han, Xin, Sun, Zhongquan, Tang, Jinlong, Wu, Yingsheng, Wang, Weilin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435785/ https://www.ncbi.nlm.nih.gov/pubmed/34527576 http://dx.doi.org/10.3389/fonc.2021.691380

Ejemplares similares

Adjuvant therapy for cholangiocarcinoma after surgery and prognosis factors for cholangiocarcinoma: A single-center retrospective cohort study
por: Sun, Zhongquan, et al.
Publicado: (2023)

Sintilimab Combined with Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma in Second-Line Setting—A Multi-Center Observational Study
por: Ding, Xiaoyan, et al.
Publicado: (2022)

Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review
por: Zhang, Wei, et al.
Publicado: (2023)

Lenvatinib Combined With a PD-1 Inhibitor as Effective Therapy for Advanced Intrahepatic Cholangiocarcinoma
por: Xie, Lulu, et al.
Publicado: (2022)

A case of toxic epidermal necrolysis associated with lenvatinib and sintilimab therapy for intrahepatic cholangiocarcinoma
por: Gong, Yinhua, et al.
Publicado: (2023)

Case report: Conversion therapy for advanced intrahepatic cholangiocarcinoma using PD-1 inhibitor plus S-1 and nab-paclitaxel
por: Li, Xiaocheng, et al.
Publicado: (2022)

Recurrent Intrahepatic Cholangiocarcinoma – Review
por: Bekki, Yuki, et al.
Publicado: (2021)

M2 macrophage inhibits the antitumor effects of Lenvatinib on intrahepatic cholangiocarcinoma
por: Yang, Long, et al.
Publicado: (2023)

A Retrospective Study of Lenvatinib Monotherapy or Combined With Programmed Cell Death Protein 1 Antibody in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma in China
por: Zhu, Sihui, et al.
Publicado: (2021)

Comparison analysis of PD-1/PD-L1 inhibitors plus lenvatinib or gemcitabine/cisplatin as first-line treatment for patients with advanced intrahepatic cholangiocarcinoma
por: Huang, Jia-Xin, et al.
Publicado: (2023)

Prostatic metastasis from intrahepatic cholangiocarcinoma
por: Tosev, Georgi, et al.
Publicado: (2018)

Locoregional Therapy for Intrahepatic Cholangiocarcinoma
por: Owen, Mackenzie, et al.
Publicado: (2023)

Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study
por: Wang, Lijun, et al.
Publicado: (2023)

Development and Validation of a Nomogram for Differentiating Combined Hepatocellular Cholangiocarcinoma From Intrahepatic Cholangiocarcinoma
por: Wang, Tao, et al.
Publicado: (2020)

Case Report: Primary lymphoepithelioma-like intrahepatic cholangiocarcinoma
por: Liu, Fei, et al.
Publicado: (2023)

Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma
por: Chun, Yun Shin, et al.
Publicado: (2017)

Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma
por: Chen, Xing, et al.
Publicado: (2022)

Lenvatinib inhibits intrahepatic cholangiocarcinoma via Gadd45a-mediated cell cycle arrest
por: Yan, Xia, et al.
Publicado: (2023)

Novel Nomogram for Preoperative Prediction of Early Recurrence in Intrahepatic Cholangiocarcinoma
por: Liang, Wenjie, et al.
Publicado: (2018)

Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors
por: Li, Xingzhi, et al.
Publicado: (2023)

Case report: A report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy
por: Zhang, Xi, et al.
Publicado: (2022)

Intraoperative Conversion to ALPPS in a Case of Intrahepatic Cholangiocarcinoma
por: Oldhafer, F., et al.
Publicado: (2015)

Dual-Specificity Phosphatase 11 Is a Prognostic Biomarker of Intrahepatic Cholangiocarcinoma
por: Xu, Lin, et al.
Publicado: (2021)

Importance of Normalization of Carbohydrate Antigen 19-9 in Patients With Intrahepatic Cholangiocarcinoma
por: Li, Hui, et al.
Publicado: (2021)

A Metastatic Intrahepatic Cholangiocarcinoma With HPCs Features: Report of a Case
por: Fu, Qiang, et al.
Publicado: (2022)

Identification of macrophage correlated biomarkers to predict the prognosis in patients with intrahepatic cholangiocarcinoma
por: Xu, Linping, et al.
Publicado: (2022)

Intrahepatic cholangiocarcinoma: The role of liver transplantation, adjunctive treatments, and prognostic biomarkers
por: Connor, Ashton A., et al.
Publicado: (2022)

Proposal for a new N-stage classification system for intrahepatic cholangiocarcinoma
por: Liao, Shan, et al.
Publicado: (2023)

Locoregional Therapy for Intrahepatic Cholangiocarcinoma: The Role of Intra-Arterial Therapies
por: Gorji, Leva, et al.
Publicado: (2023)

Conversion Therapy of Intrahepatic Cholangiocarcinoma Is Associated with Improved Prognosis and Verified by a Case of Patient-Derived Organoid
por: Wang, Zhiwei, et al.
Publicado: (2021)

Severe thyrotoxicosis induced by tislelizumab: a case report and literature review
por: Huo, Liman, et al.
Publicado: (2023)

Development and Validation of a Radiomic-Based Model for Prediction of Intrahepatic Cholangiocarcinoma in Patients With Intrahepatic Lithiasis Complicated by Imagologically Diagnosed Mass
por: Xue, Beihui, et al.
Publicado: (2021)

Downregulation of Fat Mass and Obesity Associated (FTO) Promotes the Progression of Intrahepatic Cholangiocarcinoma
por: Rong, Zhuo-Xian, et al.
Publicado: (2019)

Risk Factors and Outcomes of Early Relapse After Curative Resection of Intrahepatic Cholangiocarcinoma
por: Yang, Hua, et al.
Publicado: (2019)

Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma
por: Massa, Annamaria, et al.
Publicado: (2022)

Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine
por: Gao, Yang, et al.
Publicado: (2021)

Personalized intrahepatic cholangiocarcinoma prognosis prediction using radiomics: Application and development trend
por: Chen, Pengyu, et al.
Publicado: (2023)

Lenvatinib Beyond First-Line Therapy in Patients With Advanced Biliary Tract Carcinoma
por: Wang, Yunchao, et al.
Publicado: (2022)

Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study
por: Yi, Yong, et al.
Publicado: (2022)

Conversion therapy for advanced penile cancer with tislelizumab combined with chemotherapy: A case report and review of literature
por: Long, Xiang-Yu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6phq14sisvbsue7jpfkh91svbg